027sek
-3,5 %
Date:2024-04-25Time:17:29:00Latest report:Q4-2023List:First NorthTicker:XINT
Market Cap:155 msekEnterprise Value:148 msekNet Sales:0,08 msekEarnings:-54,1 msekEmployees:0ISIN:SE0007756903

Ratios

10-year key figure history for Xintela turnover, profit, dividend, equity, PE and PB.

Pre
Pre

Stockprice

Price movement for Xintela with index and moving average MA50 and MA200.

Stockprice:0,27
MA50:0,26
MA200:0,26
Price/MA200:5,3 %
RSI (14):51,9
Price/MA50:4,6 %

Description

Xintela AB is a biomedical company which utilises its proprietary marker technology XINMARK to develop stem cell-based therapies (XSTEM) for osteoarthritis and antibody-based therapies for Glioblastoma and Tripple-negative breast cancer. XSTEM is also evaluated for the treatment of the severe and deadly lung complication ARDS, which may affect covid-19 patients.

Biotechnology